Tempus AI Stock Falls as Personalis Deal Concerns Mount

Shares of Tempus AI (NASDAQ: TEM) fell more than 4% in morning trading Monday, extending a multi-day slide driven by investor apprehension over its planned acquisition of cancer-testing firm Personalis (NASDAQ: PSNL).

Acquisition Triggers Sell-Off

The primary pressure on Tempus shares stems from its July 20 announcement of a $1.5 billion deal to acquire Personalis. The transaction is structured mostly as an all-stock deal, which has raised concerns among investors about the dilution of existing shares. This marks the third straight session of declines for the stock since the merger was announced.

Adding to the negative sentiment, analysts have voiced caution about the acquisition's strategic and financial implications. Jefferies reiterated an Underperform rating and a $35 price target on Tempus, citing concerns about the deal's impact on the company's focus. Furthermore, Personalis is projected to post an adjusted EBITDA loss of approximately $90 million in 2027, which complicates Tempus's own goal of achieving positive EBITDA and free cash flow in the same year.

Ad

Deal Risk and Market Headwinds

The sell-off has pushed Tempus's stock price dangerously close to a critical level outlined in the merger agreement. The deal includes a termination clause that allows Personalis to withdraw if Tempus's stock price falls below $46.00.

With the stock trading at $46.96 on Monday, this introduces significant deal-risk uncertainty for investors. A muted broader market, with the Nasdaq slipping 0.3%, provided little support. While Tempus also announced the national launch of its OneOme pharmacogenomics test, the positive product news was insufficient to offset the selling pressure related to the acquisition. Investors are now looking toward the company's second-quarter earnings report on July 30 for further guidance on the integration plan and its path to profitability.